Related Experiment Video
Updated: Jun 1, 2025

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
Published on: February 9, 2021
A Comprehensive Appraisal of Bisbenzylisoquinoline Alkaloids Isolated From Genus Cyclea for Anticancer Potential
Alisha Valsan1,2, Vishnu K Omanakuttan1,2, Kokuvayil Vasu Radhakrishnan1,2
1Chemical Sciences and Technology Division, CSIR-National Institute for Interdisciplinary Science and Technology (CSIR-NIIST), Thiruvananthapuram, India.
Abstract:
The pharmaceutical industry and academia are continuously searching for novel and effective anticancer lead compounds to ensure patient safety, provide a cure, and surpass all other obstacles. Given the indeterminate nature of cancer etiology, the importance of drugs capable of targeting multiple pathways cannot be overstated. Among naturally occurring compounds, bisbenzylisoquinoline (BBIQ) alkaloids, such as berberine, tetrandrine, chelidonine, and berbamine, have demonstrated significant anticancer potential by modulating diverse signaling pathways. Several of these compounds are currently in clinical trials, highlighting their relevance in cancer treatment. This review emphasizes the need for further investigation into the anticancer properties of BBIQ alkaloids, particularly those isolated from eight Cyclea species in India. With around 27 BBIQ alkaloids identified, these compounds hold promise, especially in combating multidrug resistance-a critical challenge in cancer therapy. Given the rising cancer incidence, these alkaloids warrant a deeper exploration of their therapeutic potential.
Insights
Bisbenzylisoquinoline (BBIQ) alkaloids show significant anticancer potential, especially against multidrug resistance. Further research into these compounds, particularly from Indian Cyclea species, is crucial for developing new cancer therapies.
Area of Science:
- Pharmacology
- Natural Products Chemistry
- Oncology
Background:
- The search for novel anticancer lead compounds is ongoing due to cancer's complex etiology.
- Multidrug resistance remains a critical challenge in cancer therapy.
- Bisbenzylisoquinoline (BBIQ) alkaloids exhibit promising anticancer activities by targeting diverse signaling pathways.
Purpose of the Study:
- To review the anticancer potential of BBIQ alkaloids, with a focus on those from Indian Cyclea species.
- To highlight the therapeutic promise of BBIQ alkaloids in overcoming multidrug resistance.
- To emphasize the need for further investigation into these natural compounds for cancer treatment.
Main Methods:
- Literature review of existing studies on BBIQ alkaloids and their anticancer properties.
- Identification and characterization of BBIQ alkaloids from various plant sources, including eight Indian Cyclea species.
- Analysis of signaling pathways modulated by BBIQ alkaloids in cancer models.
Main Results:
- Approximately 27 BBIQ alkaloids have been identified with demonstrated anticancer potential.
- Several BBIQ alkaloids are currently undergoing clinical trials.
- BBIQ alkaloids show efficacy in modulating diverse cancer-related signaling pathways and combating multidrug resistance.
Conclusions:
- BBIQ alkaloids represent a promising class of natural compounds for cancer drug discovery.
- Further exploration of BBIQ alkaloids, especially those from Indian Cyclea species, is warranted.
- These compounds hold significant potential for developing novel therapeutic strategies against multidrug-resistant cancers.
More Related Videos
Related Concept Videos
Inhibition of Cdk Activity
Positive Regulator Molecules
Drugs that Stabilize Microtubules
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Drugs that Destabilize Microtubules
The Cell Cycle Control System

